Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Casarrubios M, Salas Antón C, Parra ER, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermúdez A. Provencio M, et al. Among authors: nadal e. Lancet Oncol. 2020 Nov;21(11):1413-1422. doi: 10.1016/S1470-2045(20)30453-8. Epub 2020 Sep 24. Lancet Oncol. 2020. PMID: 32979984 Clinical Trial.
Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.
Cardenal F, Arnaiz MD, Morán T, Jové J, Nadal E, Porta R, Solé JM, Brao I, Palmero R, Fuentes R, Núñez I, Caveda E, Cassinello A. Cardenal F, et al. Among authors: nadal e. Lung Cancer. 2011 Oct;74(1):69-74. doi: 10.1016/j.lungcan.2011.01.021. Epub 2011 Feb 24. Lung Cancer. 2011. PMID: 21353323 Clinical Trial.
A prognostic DNA methylation signature for stage I non-small-cell lung cancer.
Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, Sanchez-Cespedes M, Assenov Y, Müller F, Bock C, Taron M, Mora J, Muscarella LA, Liloglou T, Davies M, Pollan M, Pajares MJ, Torre W, Montuenga LM, Brambilla E, Field JK, Roz L, Lo Iacono M, Scagliotti GV, Rosell R, Beer DG, Esteller M. Sandoval J, et al. Among authors: nadal e. J Clin Oncol. 2013 Nov 10;31(32):4140-7. doi: 10.1200/JCO.2012.48.5516. Epub 2013 Sep 30. J Clin Oncol. 2013. PMID: 24081945 Free article.
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.
García-Campelo R, Bernabé R, Cobo M, Corral J, Coves J, Dómine M, Nadal E, Rodriguez-Abreu D, Viñolas N, Massuti B. García-Campelo R, et al. Among authors: nadal e. Clin Transl Oncol. 2015 Dec;17(12):1020-9. doi: 10.1007/s12094-015-1455-z. Epub 2015 Dec 21. Clin Transl Oncol. 2015. PMID: 26691657 Free PMC article.
Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.
Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, Prat A. Reguart N, et al. Among authors: nadal e. Clin Chem. 2017 Mar;63(3):751-760. doi: 10.1373/clinchem.2016.265314. Epub 2017 Jan 10. Clin Chem. 2017. PMID: 28073897
Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.
Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, Navarro A, Condom E, Moran S, Gomez-Lopez G, Graña O, Rubio-Camarillo M, Martinez-Martí A, Yokota J, Carretero J, Galbis JM, Nadal E, Pisano D, Sozzi G, Felip E, Montuenga LM, Roz L, Villanueva A, Sanchez-Cespedes M. Pereira C, et al. Among authors: nadal e. Clin Cancer Res. 2017 Jun 15;23(12):3203-3213. doi: 10.1158/1078-0432.CCR-16-1946. Epub 2017 Mar 16. Clin Cancer Res. 2017. PMID: 28302866
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer HG, Vivancos A. Martinez-Marti A, et al. Among authors: nadal e. Ann Oncol. 2017 Oct 1;28(10):2451-2457. doi: 10.1093/annonc/mdx396. Ann Oncol. 2017. PMID: 28961841 Free PMC article.
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K. Reck M, et al. Among authors: nadal e. Clin Lung Cancer. 2018 May;19(3):213-220.e4. doi: 10.1016/j.cllc.2017.11.003. Epub 2017 Nov 21. Clin Lung Cancer. 2018. PMID: 29317191 Free article. Clinical Trial.
Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer.
Antonio M, Saldaña J, Linares J, Ruffinelli JC, Palmero R, Navarro A, Arnaiz MD, Brao I, Aso S, Padrones S, Navarro V, González-Barboteo J, Borràs JM, Cardenal F, Nadal E. Antonio M, et al. Among authors: nadal e. Br J Cancer. 2018 Mar 6;118(5):639-647. doi: 10.1038/bjc.2017.455. Epub 2018 Jan 30. Br J Cancer. 2018. PMID: 29381689 Free PMC article.
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer.
Zugazagoitia J, Biosca M, Oliveira J, Olmedo ME, Dómine M, Nadal E, Ruffinelli JC, Muñoz N, Luna AM, Hernández B, Martínez M, Gallego I, Martínez de Castro E, Font C, Calvo V, Martínez-Marín V, Corral J, Noguerón E, Mondéjar R, García Escobar I, Salvador-Coloma C, Juan Ó, Sánchez Cánovas M, Valdivia J, Ochoa MP, López Castro R, Obispo B, Pangua C, Sereno M, Fernández Franco L, Mielgo X, Calzas J, Blasco A, Aparisi F, Chara L, Grau JF, Soares M, Gómez A, Zenzola V, García-Morillo M, Cacho D, Díaz-Serrano A, Aguado C, Ponce-Aix S, González-Larriba JL, Muñoz AJ, Lora D, Paz-Ares L, Manzano A. Zugazagoitia J, et al. Among authors: nadal e. Eur Respir J. 2018 May 3;51(5):1702431. doi: 10.1183/13993003.02431-2017. Print 2018 May. Eur Respir J. 2018. PMID: 29563169 Free article. No abstract available.
Preoperative nutritional status assessment predicts postoperative outcomes in patients with surgically resected non-small cell lung cancer.
Ramos R, Nadal E, Peiró I, Masuet-Aumatell C, Macia I, Rivas F, Rosado G, Rodriguez P, Ureña A, Padrones S, Aso S, Deniz C, Navarro A, Escobar I. Ramos R, et al. Among authors: nadal e. Eur J Surg Oncol. 2018 Sep;44(9):1419-1424. doi: 10.1016/j.ejso.2018.03.026. Epub 2018 Apr 11. Eur J Surg Oncol. 2018. PMID: 29685760
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Socinski MA, et al. N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4. N Engl J Med. 2018. PMID: 29863955 Free article. Clinical Trial.
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.
Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M. Duruisseaux M, et al. Among authors: nadal e. Lancet Respir Med. 2018 Oct;6(10):771-781. doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9. Lancet Respir Med. 2018. PMID: 30100403 Free article.
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguet AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, De Ruysscher D. Peters S, et al. Among authors: nadal e. Lung Cancer. 2019 Jul;133:83-87. doi: 10.1016/j.lungcan.2019.05.001. Epub 2019 May 3. Lung Cancer. 2019. PMID: 31200833 Clinical Trial.
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Nakagawa K, et al. Among authors: nadal e. Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4. Lancet Oncol. 2019. PMID: 31591063 Clinical Trial.
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.
Fernandes Neto JM, Nadal E, Bosdriesz E, Ooft SN, Farre L, McLean C, Klarenbeek S, Jurgens A, Hagen H, Wang L, Felip E, Martinez-Marti A, Vidal A, Voest E, Wessels LFA, van Tellingen O, Villanueva A, Bernards R. Fernandes Neto JM, et al. Among authors: nadal e. Nat Commun. 2020 Jun 22;11(1):3157. doi: 10.1038/s41467-020-16952-9. Nat Commun. 2020. PMID: 32572029 Free PMC article.
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
Remon J, Nadal E, Dómine M, Ruffinelli J, García Y, Pardo JC, López R, Cilleruelo A, García-Campelo R, Martín P, Juan O, González-Larriba JL, Provencio M, Olmedo E, Ponce S, Cumplido D, Barenys C, Majem M, Massutti B, Rodriguez-Abreu D, Porta R, Sala MA, Martinez-Kareaga M, Lianes P, Reguart N. Remon J, et al. Among authors: nadal e. Lung Cancer. 2020 Sep;147:83-90. doi: 10.1016/j.lungcan.2020.06.034. Epub 2020 Jul 3. Lung Cancer. 2020. PMID: 32682189
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O'Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Nadal E, Janthur WD, López Castro R, García Campelo R, Rusakiewicz S, Letovanec I, Polydoropoulou V, Roschitzki-Voser H, Ruepp B, Gasca-Ruchti A, Peters S, Stahel RA. Popat S, et al. Among authors: nadal e. Ann Oncol. 2020 Dec;31(12):1734-1745. doi: 10.1016/j.annonc.2020.09.009. Epub 2020 Sep 22. Ann Oncol. 2020. PMID: 32976938 Free article. Clinical Trial.
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14).
Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Álvarez R, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Lambrecht M, Andratschke N, Tsourti Z, Piguet AC, Roschitzki-Voser H, Gasca-Ruchti A, Vansteenkiste J, Stahel RA, De Ruysscher D. Peters S, et al. Among authors: nadal e. J Thorac Oncol. 2021 Feb;16(2):278-288. doi: 10.1016/j.jtho.2020.10.129. Epub 2020 Nov 12. J Thorac Oncol. 2021. PMID: 33188912 Free article. Clinical Trial.
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
Goldman JW, Mazieres J, Barlesi F, Dragnev KH, Koczywas M, Göskel T, Cortot AB, Girard N, Wesseler C, Bischoff H, Nadal E, Park K, Lu S, Taus A, Cobo M, Estrem ST, Wijayawardana SR, Turner K, Oakley GJ 3rd, Hurt KC, Chiang AY, Hossain AM, John WJ, Paz-Ares L. Goldman JW, et al. Among authors: nadal e. Front Oncol. 2020 Oct 26;10:578756. doi: 10.3389/fonc.2020.578756. eCollection 2020. Front Oncol. 2020. PMID: 33194700 Free PMC article.
SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020).
Nadal E, Bosch-Barrera J, Cedrés S, Coves J, García-Campelo R, Guirado M, López-Castro R, Ortega AL, Vicente D, de Castro-Carpeño J. Nadal E, et al. Clin Transl Oncol. 2021 May;23(5):980-987. doi: 10.1007/s12094-020-02532-2. Epub 2021 Feb 4. Clin Transl Oncol. 2021. PMID: 33538989 Free PMC article. Review.
Lung cancer patients with COVID-19 in Spain: GRAVID study.
Provencio M, Mazarico Gallego JM, Calles A, Antoñanzas M, Pangua C, Mielgo Rubio X, Nadal E, Castro RL, López-Martín A, Del Barco E, Dómine M, Franco F, Diz P, Sandoval C, Girona ES, Sullivan I, Sala MÁ, Ledo GG, Cucurull M, Mosquera J, Martínez M, Chara LE, Arriola E, Herrera BE, Jarabo JR, Álvarez RÁ, Baena J, Cao MG. Provencio M, et al. Among authors: nadal e. Lung Cancer. 2021 Jul;157:109-115. doi: 10.1016/j.lungcan.2021.05.014. Epub 2021 May 14. Lung Cancer. 2021. PMID: 34016490 Free PMC article.
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.
Laza-Briviesca R, Cruz-Bermúdez A, Nadal E, Insa A, García-Campelo MDR, Huidobro G, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Casarrubios M, Sierra-Rodero B, Tarín C, García-Grande A, Haymaker C, Wistuba II, Romero A, Franco F, Provencio M. Laza-Briviesca R, et al. Among authors: nadal e. Clin Transl Med. 2021 Jul;11(7):e491. doi: 10.1002/ctm2.491. Clin Transl Med. 2021. PMID: 34323406 Free PMC article.
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.
Casarrubios M, Cruz-Bermúdez A, Nadal E, Insa A, García Campelo MDR, Lázaro M, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, de Castro-Carpeño J, Cobo M, López-Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Barquín M, Laza-Briviesca R, Sierra-Rodero B, Parra ER, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba II, Romero A, Calvo V, Provencio M. Casarrubios M, et al. Among authors: nadal e. Clin Cancer Res. 2021 Nov 1;27(21):5878-5890. doi: 10.1158/1078-0432.CCR-21-1200. Epub 2021 Aug 10. Clin Cancer Res. 2021. PMID: 34376534 Free PMC article.
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial.
Sierra-Rodero B, Cruz-Bermúdez A, Nadal E, Garitaonaindía Y, Insa A, Mosquera J, Casal-Rubio J, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, García-Grande A, Romero A, Franco F, Provencio M. Sierra-Rodero B, et al. Among authors: nadal e. J Immunother Cancer. 2021 Aug;9(8):e002804. doi: 10.1136/jitc-2021-002804. J Immunother Cancer. 2021. PMID: 34446577 Free PMC article.
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S; ETOP 10-16 BOOSTER Collaborators. Soo RA, et al. Among authors: nadal e. Ann Oncol. 2022 Feb;33(2):181-192. doi: 10.1016/j.annonc.2021.11.010. Epub 2021 Nov 26. Ann Oncol. 2022. PMID: 34839016 Free article. Clinical Trial.
Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
Palmero R, Taus A, Viteri S, Majem M, Carcereny E, Garde-Noguera J, Felip E, Nadal E, Malfettone A, Sampayo M, Riva F, Nagy RJ, Lanman RB, Faull I, Dix D, Karachaliou N, Rosell R. Palmero R, et al. Among authors: nadal e. JCO Precis Oncol. 2021 Nov;5:93-102. doi: 10.1200/PO.20.00241. JCO Precis Oncol. 2021. PMID: 34994593
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study.
Provencio M, Rodríguez-Abreu D, Ortega AL, Serrano G, Aguado C, Franco F, Gutierrez V, López Vivanco G, Guirado M, Benítez G, Estival A, Calvo V, Jiménez B, Arasanz H, Coves J, Majem M, Massutí B, Vázquez S, Juan-Vidal O, Collazo-Lorduy A, Gozálvez CL, Del Barco E, Rosero A, Bosch-Barrerra J, Moreno MA, Mielgo-Rubio X, Villa JC, López-Martin A, Córdoba JF, de Asís Aparisi F, Zafra M, Mosquera J, Pérez Altozano J, Nadal E, Catot S, Balsalobre J, de Portugal T, Martín P, Cuesta de Juan S, Cobo M. Provencio M, et al. Among authors: nadal e. Transl Lung Cancer Res. 2022 Jan;11(1):53-63. doi: 10.21037/tlcr-21-504. Transl Lung Cancer Res. 2022. PMID: 35242627 Free PMC article.
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Lobefaro R, López-Castro R, Bosch-Barrera J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Aboubakar-Nana F, Ponce S, Dal Maso A, Spotti M, Mielgo-Rubio X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier J, Audigier-Valette C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia-Campelo R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Planchard D, Mezquita L. Riudavets M, et al. Among authors: nadal e. Eur J Cancer. 2022 May;167:142-148. doi: 10.1016/j.ejca.2022.02.014. Epub 2022 Mar 17. Eur J Cancer. 2022. PMID: 35307254
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).
Provencio M, Serna-Blasco R, Nadal E, Insa A, García-Campelo MR, Casal Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Calvo V, Martín-López J, García-García F, Casarrubios M, Franco F, Sánchez-Herrero E, Massuti B, Cruz-Bermúdez A, Romero A. Provencio M, et al. Among authors: nadal e. J Clin Oncol. 2022 Sep 1;40(25):2924-2933. doi: 10.1200/JCO.21.02660. Epub 2022 May 16. J Clin Oncol. 2022. PMID: 35576508 Free PMC article. Clinical Trial.
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
Dafni U, Soo RA, Peters S, Tsourti Z, Zygoura P, Vervita K, Han JY, De Castro J, Coate L, Früh M, Hashemi SMS, Nadal E, Carcereny E, Sala MA, Bernabé R, Provencio M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA. Dafni U, et al. Among authors: nadal e. ESMO Open. 2022 Jun;7(3):100507. doi: 10.1016/j.esmoop.2022.100507. Epub 2022 Jun 10. ESMO Open. 2022. PMID: 35696746 Free PMC article.
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Casarrubios M, Provencio M, Nadal E, Insa A, Del Rosario García-Campelo M, Lázaro-Quintela M, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé R, Viñolas N, Barneto Aranda I, Massuti B, Sierra-Rodero B, Martinez-Toledo C, Fernández-Miranda I, Serna-Blanco R, Romero A, Calvo V, Cruz-Bermúdez A. Casarrubios M, et al. Among authors: nadal e. J Immunother Cancer. 2022 Sep;10(9):e005320. doi: 10.1136/jitc-2022-005320. J Immunother Cancer. 2022. PMID: 36171009 Free PMC article. Clinical Trial.
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer.
Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussain M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE. Riely GJ, et al. Among authors: nadal e. J Clin Oncol. 2023 Jul 20;41(21):3700-3711. doi: 10.1200/JCO.23.00774. Epub 2023 Jun 4. J Clin Oncol. 2023. PMID: 37270692 Clinical Trial.
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, López Vivanco G, Camps C, López-Castro R, Morán T, Barneto I, Rodríguez-Abreu D, Serna-Blasco R, Benítez R, Aguado de la Rosa C, Palmero R, Hernando-Trancho F, Martín-López J, Cruz-Bermúdez A, Massuti B, Romero A. Provencio M, et al. Among authors: nadal e. N Engl J Med. 2023 Aug 10;389(6):504-513. doi: 10.1056/NEJMoa2215530. Epub 2023 Jun 28. N Engl J Med. 2023. PMID: 37379158 Clinical Trial.
Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes.
Blanco R, Dómine M, González JL, Loutfi S, Alfaro J, Saldaña J, Rubio J, Campos B, Hidalgo J, Barba A, Márquez D, Martin M, Olaverri A, Nadal E. Blanco R, et al. Among authors: nadal e. Lung Cancer. 2023 Sep;183:107318. doi: 10.1016/j.lungcan.2023.107318. Epub 2023 Aug 2. Lung Cancer. 2023. PMID: 37557022 Free article. Clinical Trial.
Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer.
Nadal E, Oré-Arce M, Remon J, Bernabé-Caro R, Covela-Rúa M, de Castro-Carpeño J, Massutí-Sureda B, Guillot-Morales M, Majem M, Maestu-Maiques I, Morilla-Ruíz I, Gironés R. Nadal E, et al. Clin Transl Oncol. 2023 Nov;25(11):3139-3151. doi: 10.1007/s12094-023-03286-3. Epub 2023 Aug 11. Clin Transl Oncol. 2023. PMID: 37566345 Free PMC article.
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
Nadal E, Rodríguez-Abreu D, Simó M, Massutí B, Juan O, Huidobro G, López R, De Castro J, Estival A, Mosquera J, Sullivan I, Felip E, Blasco A, Guirado M, Pereira E, Vilariño N, Navarro V, Bruna J. Nadal E, et al. J Clin Oncol. 2023 Oct 1;41(28):4478-4485. doi: 10.1200/JCO.22.02561. Epub 2023 Aug 21. J Clin Oncol. 2023. PMID: 37603816 Free PMC article. Clinical Trial.
Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer.
Aparicio I, Iranzo P, Reyes R, Bote H, Saigi M, Bringas M, Bosch-Barrera J, Corral J, Aparisi F, Ruffinelli JC, Jiménez B, Lage Y, López-Castro R, Majem M, Vázquez S, Artal Á, Rodríguez-Pérez Á, Lázaro-Quintela M, Torres JMS, Reguart N, Cucurull M, Gil-Bazo I, Camps C, Nadal E, Del Barrio A, Garrido P, Dómine M, Álvarez R, Muñoz AJ, Calles A. Aparicio I, et al. Among authors: nadal e. Thromb Res. 2023 Dec;232:133-137. doi: 10.1016/j.thromres.2023.11.007. Epub 2023 Nov 12. Thromb Res. 2023. PMID: 37976733
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Prelaj A, López-Castro R, Bosch-Barrera J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Aboubakar Nana F, Ponce S, Albarrán-Artahona V, Dal Maso A, Spotti M, Mielgo X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier JB, Audigier-Valette C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia-Campelo R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Mezquita L, Planchard D. Riudavets M, et al. Among authors: nadal e. Clin Lung Cancer. 2024 May;25(3):233-243.e8. doi: 10.1016/j.cllc.2023.11.007. Epub 2023 Nov 22. Clin Lung Cancer. 2024. PMID: 38105153
RET Fusion Testing in Patients With NSCLC: The RETING Study.
Conde E, Hernandez S, Rodriguez Carrillo JL, Martinez R, Alonso M, Curto D, Jimenez B, Caminoa A, Benito A, Garrido P, Clave S, Arriola E, Esteban-Rodriguez I, De Castro J, Sansano I, Felip E, Rojo F, Dómine M, Abdulkader I, Garcia-Gonzalez J, Teixido C, Reguart N, Compañ D, Insa A, Mancheño N, Palanca S, Juan-Vidal O, Baixeras N, Nadal E, Cebollero M, Calles A, Martin P, Salas C, Provencio M, Aranda I, Massuti B, Lopez-Vilaro L, Majem M, Paz-Ares L, Lopez-Rios F. Conde E, et al. Among authors: nadal e. JTO Clin Res Rep. 2024 Feb 20;5(4):100653. doi: 10.1016/j.jtocrr.2024.100653. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38525319 Free PMC article.
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP.
Ospina AV, Bolufer Nadal S, Campo-Cañaveral de la Cruz JL, González Larriba JL, Macía Vidueira I, Massutí Sureda B, Nadal E, Trancho FH, Álvarez Kindelán A, Del Barco Morillo E, Bernabé Caro R, Bosch Barrera J, Calvo de Juan V, Casal Rubio J, de Castro J, Cilleruelo Ramos Á, Cobo Dols M, Dómine Gómez M, Figueroa Almánzar S, Garcia Campelo R, Insa Mollá A, Jarabo Sarceda JR, Jiménez Maestre U, López Castro R, Majem M, Martinez-Marti A, Martínez Téllez E, Sánchez Lorente D, Provencio M. Ospina AV, et al. Among authors: nadal e. Clin Transl Oncol. 2024 Jul;26(7):1647-1663. doi: 10.1007/s12094-024-03382-y. Epub 2024 Mar 26. Clin Transl Oncol. 2024. PMID: 38530556 Free PMC article. Review.
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.
Provencio M, Robado de Lope L, Serna-Blasco R, Nadal E, Diz Tain P, Massuti B, González-Larriba JL, Insa A, Sánchez-Hernández A, Casal-Rubio J, García-Campelo R, Sequero López S, Rogado J, Martínez-Martí A, Bosch-Barrera J, Bernabé R, Vázquez Estévez S, Ponce S, de Castro J, Coves Sarto J, Reguart N, Dómine M, Aguilar A, Majem M, Estival A, Peña Cabia S, López Martín A, Sala González MÁ, Cobo M, Camps C, Barneto I, Calvo V, Collazo-Lorduy A, Cruz-Bermúdez A, Romero A. Provencio M, et al. Among authors: nadal e. Lung Cancer. 2024 Aug;194:107865. doi: 10.1016/j.lungcan.2024.107865. Epub 2024 Jun 26. Lung Cancer. 2024. PMID: 38945004 Free article.
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.
Leary A, Estévez-García P, Sabatier R, Ray-Coquard I, Romeo M, Barretina-Ginesta P, Gil-Martin M, Garralda E, Bosch-Barrera J, Morán T, Martin-Martorell P, Nadal E, Gascón P, Rodon J, Lizcano JM, Muñoz-Guardiola P, Fierro-Durán G, Pedrós-Gámez O, Pérez-Montoyo H, Yeste-Velasco M, Cortal M, Pérez-Campos A, Alfon J, Domenech C, Pérez-Fidalgo A, Oaknin A. Leary A, et al. Among authors: nadal e. BMC Cancer. 2024 Jul 22;24(1):876. doi: 10.1186/s12885-024-12501-5. BMC Cancer. 2024. PMID: 39039449 Free PMC article. Clinical Trial.
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.
Arriola E, de Castro J, García-Campelo R, Bernárdez B, Bernabé R, Bruna J, Dómine M, Isla D, Juan-Vidal Ó, López-Fernández T, Nadal E, Rodríguez-Abreu D, Vares M, Asensio Ú, García LF, Felip E. Arriola E, et al. Among authors: nadal e. Clin Drug Investig. 2024 Aug;44(8):553-576. doi: 10.1007/s40261-024-01379-7. Epub 2024 Jul 31. Clin Drug Investig. 2024. PMID: 39085682 Free PMC article. Review.
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, Hayashi H, Nhung NV, Chia PL, de Marinis F, Raskin J, Zhou Q, Finocchiaro G, Le AT, Wang J, Dooms C, Kato T, Nadal E, Hin HS, Smit EF, Wermke M, Tan D, Morise M, O'Brate A, Adrian S, Pfeiffer BM, Stroh C, Juraeva D, Strotmann R, Goteti K, Berghoff K, Ellers-Lenz B, Karachaliou N, Le X, Kim TM; INSIGHT 2 investigators. Wu YL, et al. Among authors: nadal e. Lancet Oncol. 2024 Aug;25(8):989-1002. doi: 10.1016/S1470-2045(24)00270-5. Lancet Oncol. 2024. PMID: 39089305 Clinical Trial.
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.
Provencio M, Nadal E, Insa A, García Campelo R, Casal J, Dómine M, Massuti B, Majem M, Rodríguez-Abreu D, Martínez-Martí A, de Castro J, Gómez de Antonio D, Macia I, Figueroa S, Fernández Vago L, Calvo V, Palmero R, Sierra-Rodero B, Martínez-Toledo C, Molina-Alejandre M, Serna-Blasco R, Romero A, Cruz-Bermúdez A. Provencio M, et al. Among authors: nadal e. Lancet Oncol. 2024 Nov;25(11):1453-1464. doi: 10.1016/S1470-2045(24)00498-4. Epub 2024 Oct 14. Lancet Oncol. 2024. PMID: 39419061 Free PMC article. Clinical Trial.
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.
Molina-Alejandre M, Perea F, Calvo V, Martinez-Toledo C, Nadal E, Sierra-Rodero B, Casarrubios M, Casal-Rubio J, Martinez-Martí A, Insa A, Massuti B, Viteri S, Barneto Aranda I, Rodriguez-Abreu D, de Castro J, Martínez JM, Cobo M, Wistuba II, Parra ER, Martín-López J, Megías D, Muñoz-Viana R, Garrido F, Aptsiauri N, Ruiz-Cabello F, Provencio M, Cruz-Bermúdez A. Molina-Alejandre M, et al. Among authors: nadal e. J Immunother Cancer. 2024 Oct 20;12(10):e009762. doi: 10.1136/jitc-2024-009762. J Immunother Cancer. 2024. PMID: 39428126 Free PMC article.
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.
Felip E, Popat S, Dafni U, Ribi K, Pope A, Cedres S, Shah R, de Marinis F, Cove Smith L, Bernabé R, Früh M, Nackaerts K, Greillier L, Scherz A, Massuti B, Nadal E, Vila Martinez L, Talbot T, Roschitzki-Voser H, Dimopoulou G, Schär S, Ruepp B, Savic S, Peters S, Stahel R; ETOP 13-18 BEAT-meso Collaborators. Felip E, et al. Among authors: nadal e. Ann Oncol. 2025 May;36(5):548-560. doi: 10.1016/j.annonc.2024.12.014. Epub 2025 Jan 13. Ann Oncol. 2025. PMID: 39814199 Clinical Trial.
Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma.
Nadal E, Martín-Martorell P, Benítez JC, Sala MÁ, Cedrés S, Álvarez C, Dómine M, Sais E, Saigí M, López R, Vilà L, Massutí B, García-Campelo R, Mesas-Ruiz A, Insa A, Plans-Marín S, Hijazo-Pechero S, Muñoz-Pinedo C, Brenes J, Provencio M; Spanish Lung Cancer Group. Nadal E, et al. Lung Cancer. 2025 May;203:108545. doi: 10.1016/j.lungcan.2025.108545. Epub 2025 Apr 17. Lung Cancer. 2025. PMID: 40253943 Free article. Clinical Trial.
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer.
Garon EB, Reck M, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Lee P, Dalal R, Liu J, He S, Treat J, Nakagawa K. Garon EB, et al. Among authors: nadal e. Clin Lung Cancer. 2017 Jan;18(1):96-99. doi: 10.1016/j.cllc.2016.05.023. Epub 2016 Jun 8. Clin Lung Cancer. 2017. PMID: 27894601 Clinical Trial.
Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Bergamino M, Rullan AJ, Saigí M, Peiró I, Montanya E, Palmero R, Ruffinelli JC, Navarro A, Arnaiz MD, Brao I, Aso S, Padrones S, Cardenal F, Nadal E. Bergamino M, et al. Among authors: nadal e. BMC Cancer. 2019 Feb 21;19(1):165. doi: 10.1186/s12885-019-5370-5. BMC Cancer. 2019. PMID: 30791870 Free PMC article.
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Ramalingam SS, et al. N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21. N Engl J Med. 2020. PMID: 31751012 Free article. Clinical Trial.
Molecular Nodal Restaging Based on CEACAM5, FGFR2b and PTPN11 Expression Adds No Relevant Clinical Information in Resected Non-Small Cell Lung Cancer.
Macia I, Aiza G, Ramos R, Escobar I, Rivas F, Ureña A, Aso S, Rosado G, Rodriguez-Taboada P, Deniz C, Nadal E, Capella G. Macia I, et al. Among authors: nadal e. J Invest Surg. 2022 Feb;35(2):315-324. doi: 10.1080/08941939.2020.1857479. Epub 2020 Dec 21. J Invest Surg. 2022. PMID: 33342327 Free article.
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
Ponce Aix S, Novello S, Garon EB, Nakagawa K, Nadal E, Moro-Sibilot D, Alonso Garcia M, Fabre E, Frimodt-Moller B, Zimmermann AH, Visseren-Grul CM, Reck M; RELAY investigators. Ponce Aix S, et al. Among authors: nadal e. Cancer Treat Res Commun. 2021;27:100378. doi: 10.1016/j.ctarc.2021.100378. Epub 2021 Apr 19. Cancer Treat Res Commun. 2021. PMID: 33905962 Free article. Clinical Trial.
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, Park W, Nadal E, Martin-Romano P, Ruffinelli JC, Ponce S, Audigier-Valette C, Carnio S, Blanc-Durand F, Bironzo P, Tabbò F, Reale ML, Novello S, Hellmann MD, Sawan P, Girshman J, Plodkowski AJ, Zalcman G, Majem M, Charrier M, Naigeon M, Rossoni C, Mariniello A, Paz-Ares L, Dingemans AM, Planchard D, Cozic N, Cassard L, Lopes G, Chaput N, Arbour K, Besse B. Mezquita L, et al. Among authors: nadal e. Eur J Cancer. 2021 Jul;151:211-220. doi: 10.1016/j.ejca.2021.03.011. Epub 2021 May 19. Eur J Cancer. 2021. PMID: 34022698
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.
Nakagawa K, Nadal E, Garon EB, Nishio M, Seto T, Yamamoto N, Park K, Shih JY, Paz-Ares L, Frimodt-Moller B, Zimmermann AH, Wijayawardana S, Visseren-Grul C, Reck M. Nakagawa K, et al. Among authors: nadal e. Clin Cancer Res. 2021 Oct 1;27(19):5258-5271. doi: 10.1158/1078-0432.CCR-21-0273. Clin Cancer Res. 2021. PMID: 34301751 Free PMC article. Clinical Trial.
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort.
Dziadziuszko R, Mok T, Peters S, Han JY, Alatorre-Alexander J, Leighl N, Sriuranpong V, Pérol M, de Castro Junior G, Nadal E, de Marinis F, Frontera OA, Tan DSW, Lee DH, Kim HR, Yan M, Riehl T, Schleifman E, Paul SM, Mocci S, Patel R, Assaf ZJ, Shames DS, Mathisen MS, Gadgeel SM. Dziadziuszko R, et al. Among authors: nadal e. J Thorac Oncol. 2021 Dec;16(12):2040-2050. doi: 10.1016/j.jtho.2021.07.008. Epub 2021 Jul 24. J Thorac Oncol. 2021. PMID: 34311110 Free article. Clinical Trial.
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance.
F Smit E, Dooms C, Raskin J, Nadal E, Tho LM, Le X, Mazieres J, S Hin H, Morise M, W Zhu V, Tan D, H Holmberg K, Ellers-Lenz B, Adrian S, Brutlach S, Schumacher KM, Karachaliou N, Wu YL. F Smit E, et al. Among authors: nadal e. Future Oncol. 2022 Mar;18(9):1039-1054. doi: 10.2217/fon-2021-1406. Epub 2021 Dec 17. Future Oncol. 2022. PMID: 34918545 Free article.
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
Nadal E, Horinouchi H, Shih JY, Nakagawa K, Reck M, Garon EB, Wei YF, Kollmeier J, Frimodt-Moller B, Barrett E, Lipkovich O, Visseren-Grul C, Novello S. Nadal E, et al. Drug Saf. 2022 Jan;45(1):45-64. doi: 10.1007/s40264-021-01127-2. Epub 2021 Dec 20. Drug Saf. 2022. PMID: 34928484 Free PMC article. Clinical Trial.
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).
Tabbò F, Pisano C, Mazieres J, Mezquita L, Nadal E, Planchard D, Pradines A, Santamaria D, Swalduz A, Ambrogio C, Novello S, Ortiz-Cuaran S; BOLERO Consortium. Tabbò F, et al. Among authors: nadal e. Cancer Treat Rev. 2022 Feb;103:102335. doi: 10.1016/j.ctrv.2021.102335. Epub 2021 Dec 31. Cancer Treat Rev. 2022. PMID: 35033867 Review.
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, Martin C, Reck M, Garon EB, Felip E, Paz-Ares L, Mornex F, Vokes EE, Adjei AA, Robinson C, Sato M, Vugmeyster Y, Machl A, Audhuy F, Chaudhary S, Barlesi F. Cho BC, et al. Among authors: nadal e. J Thorac Oncol. 2023 Dec;18(12):1731-1742. doi: 10.1016/j.jtho.2023.08.018. Epub 2023 Aug 18. J Thorac Oncol. 2023. PMID: 37597750 Free article. Clinical Trial.
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.
Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala MA, Coate L, Provencio M, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, Stahel RA; ETOP 10-16 BOOSTER Collaborators. Soo RA, et al. Among authors: nadal e. Clin Cancer Res. 2024 Nov 15;30(22):5180-5191. doi: 10.1158/1078-0432.CCR-24-0932. Clin Cancer Res. 2024. PMID: 39250635 Clinical Trial.
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy.
Hochmair M, Schenker M, Cobo Dols M, Kim TM, Ozyilkan O, Smagina M, Leonova V, Kato T, Fedenko A, De Angelis F, Rittmeyer A, Gray JE, Greystoke A, Aggarwal H, Huang Q, Zhao B, Lara-Guerra H, Nadal E. Hochmair M, et al. Among authors: nadal e. J Thorac Oncol. 2025 Feb;20(2):203-218. doi: 10.1016/j.jtho.2024.10.012. Epub 2024 Oct 28. J Thorac Oncol. 2025. PMID: 39477187 Free article. Clinical Trial.
Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study.
Calles A, Navarro A, Doger de Speville Uribe BG, Colomé EÁ, de Miguel M, Álvarez R, Arregui M, Moreno V, Rocha P, Calvo E, Ramon-Patino J, Corral de la Fuente E, Alcalá-López D, Boix O, Fernández-Pinto M, Rodríguez-Morató J, Palmero R, Nadal E, Jove M, Felip E. Calles A, et al. Among authors: nadal e. J Thorac Oncol. 2025 Feb 10:S1556-0864(25)00064-4. doi: 10.1016/j.jtho.2025.02.005. Online ahead of print. J Thorac Oncol. 2025. PMID: 39938593 Free article.
ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer.
Bosch-Barrera J, Estévez-García P, Martín-Martorell P, Sabatier R, Nadal E, Sais E, Gascón P, Oaknin A, Rodon J, Lizcano JM, Muñoz-Guardiola P, Fierro-Durán G, Pedrós-Gámez O, Pérez-Montoyo H, Yeste-Velasco M, Cortal M, Pérez-Campos A, Alfón J, Domènech C, Morán T. Bosch-Barrera J, et al. Among authors: nadal e. Lung Cancer. 2025 Mar;201:108105. doi: 10.1016/j.lungcan.2025.108105. Epub 2025 Feb 7. Lung Cancer. 2025. PMID: 39983444 Free article. Clinical Trial.
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Soria JC, et al. N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18. N Engl J Med. 2018. PMID: 29151359 Free article. Clinical Trial.
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.
Pros E, Saigi M, Alameda D, Gomez-Mariano G, Martinez-Delgado B, Alburquerque-Bejar JJ, Carretero J, Tonda R, Esteve-Codina A, Catala I, Palmero R, Jove M, Lazaro C, Patiño-Garcia A, Gil-Bazo I, Verdura S, Teulé A, Torres-Lanzas J, Sidransky D, Reguart N, Pio R, Juan-Vidal O, Nadal E, Felip E, Montuenga LM, Sanchez-Cespedes M. Pros E, et al. Among authors: nadal e. Ann Oncol. 2020 Feb;31(2):274-282. doi: 10.1016/j.annonc.2019.09.001. Ann Oncol. 2020. PMID: 31959344 Free article.
Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre.
Mosteiro M, Azuara D, Villatoro S, Alay A, Gausachs M, Varela M, Baixeras N, Pijuan L, Ajenjo-Bauza M, Lopez-Doriga A, Teulé Á, Solanes A, Palmero R, Brenes J, Jové M, Padrones S, Moreno V, Cordero D, Matías-Guiu X, Lázaro C, Nadal E. Mosteiro M, et al. Among authors: nadal e. ESMO Open. 2023 Dec;8(6):102197. doi: 10.1016/j.esmoop.2023.102197. Epub 2023 Dec 8. ESMO Open. 2023. PMID: 38070435 Free PMC article.
Intrinsic cancer subtypes--next steps into personalized medicine.
Santos C, Sanz-Pamplona R, Nadal E, Grasselli J, Pernas S, Dienstmann R, Moreno V, Tabernero J, Salazar R. Santos C, et al. Among authors: nadal e. Cell Oncol (Dordr). 2015 Feb;38(1):3-16. doi: 10.1007/s13402-014-0203-7. Epub 2015 Jan 14. Cell Oncol (Dordr). 2015. PMID: 25586691 Review.
A Novel Serum 4-microRNA Signature for Lung Cancer Detection.
Nadal E, Truini A, Nakata A, Lin J, Reddy RM, Chang AC, Ramnath N, Gotoh N, Beer DG, Chen G. Nadal E, et al. Sci Rep. 2015 Jul 23;5:12464. doi: 10.1038/srep12464. Sci Rep. 2015. PMID: 26202143 Free PMC article.
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Mainardi S, Mulero-Sánchez A, Prahallad A, Germano G, Bosma A, Krimpenfort P, Lieftink C, Steinberg JD, de Wit N, Gonçalves-Ribeiro S, Nadal E, Bardelli A, Villanueva A, Bernards R. Mainardi S, et al. Among authors: nadal e. Nat Med. 2018 Jul;24(7):961-967. doi: 10.1038/s41591-018-0023-9. Epub 2018 May 28. Nat Med. 2018. PMID: 29808006 Free article.
The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer.
López-Plana A, Fernández-Nogueira P, Muñoz-Guardiola P, Solé-Sánchez S, Megías-Roda E, Pérez-Montoyo H, Jauregui P, Yeste-Velasco M, Gómez-Ferreria M, Erazo T, Ametller E, Recalde-Percaz L, Moragas-Garcia N, Noguera-Castells A, Mancino M, Morán T, Nadal E, Alfón J, Domènech C, Gascon P, Lizcano JM, Fuster G, Bragado P. López-Plana A, et al. Among authors: nadal e. Int J Cancer. 2020 Aug 15;147(4):1163-1179. doi: 10.1002/ijc.32865. Epub 2020 Feb 6. Int J Cancer. 2020. PMID: 31943158
Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R, Villagrán M, Jové M, Simó M, Vilariño N, Alemany M, Palmero R, Martínez-Villacampa MM, Nadal E, Bruna J. Velasco R, et al. Among authors: nadal e. JAMA Neurol. 2021 Jul 1;78(7):864-873. doi: 10.1001/jamaneurol.2021.0249. JAMA Neurol. 2021. PMID: 33720308
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, Nadal E, Vuky J, Lopes G, Kalemkerian GP, Bowles DW, Seetharam M, Chang J, Zhang H, Green J, Zalutskaya A, Schuler M, Fan Y, Curigliano G. Subbiah V, et al. Among authors: nadal e. Nat Med. 2022 Aug;28(8):1640-1645. doi: 10.1038/s41591-022-01931-y. Epub 2022 Aug 12. Nat Med. 2022. PMID: 35962206 Free PMC article. Clinical Trial.
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer.
Auclin E, Benitez-Montanez J, Tagliamento M, Parisi F, Gorria T, Garcia-Campelo R, Dempsey N, Pinato DJ, Reyes R, Albarrán-Artahona V, Dall'Olio F, Soldato D, Hendriks L, Nana FA, Tonneau M, Lopez-Castro R, Nadal E, Kazandjian S, Muanza T, Blanc-Durand F, Fabre E, Castro N, Arasanz H, Rochand A, Besse B, Routy B, Mezquita L. Auclin E, et al. Among authors: nadal e. Lung Cancer. 2023 Apr;178:116-122. doi: 10.1016/j.lungcan.2023.02.002. Epub 2023 Feb 4. Lung Cancer. 2023. PMID: 36812760
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
Peters S, Gadgeel SM, Mok T, Nadal E, Kilickap S, Swalduz A, Cadranel J, Sugawara S, Chiu CH, Yu CJ, Moskovitz M, Tanaka T, Nersesian R, Shagan SM, Maclennan M, Mathisen M, Bhagawati-Prasad V, Diarra C, Assaf ZJ, Archer V, Dziadziuszko R. Peters S, et al. Among authors: nadal e. Nat Med. 2024 Jul;30(7):1923-1932. doi: 10.1038/s41591-024-03008-4. Epub 2024 Jun 19. Nat Med. 2024. PMID: 38898120 Free PMC article. Clinical Trial.
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, Wu YL, Cho BC, Yamamoto N, Sabari JK, Zhao Y, Tu HY, Yoh K, Nadal E, Sadrolhefazi B, Rohrbacher M, von Wangenheim U, Eigenbrod-Giese S, Zugazagoitia J; Beamion LUNG-1 Investigators. Heymach JV, et al. Among authors: nadal e. N Engl J Med. 2025 Apr 28. doi: 10.1056/NEJMoa2503704. Online ahead of print. N Engl J Med. 2025. PMID: 40293180
Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC): A Review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee.
Jones SB, Chan C, Filippi AR, Harada K, Louie AV, Lindsay CR, Nadal E, Schuffenegger PM, Woolf D, Faivre-Finn C; of the IASLC Advanced Radiation Technologies (ART) Subcommittee. Jones SB, et al. Among authors: nadal e. J Thorac Oncol. 2025 May 9:S1556-0864(25)00710-5. doi: 10.1016/j.jtho.2025.05.004. Online ahead of print. J Thorac Oncol. 2025. PMID: 40350081 Free article. Review.
Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.
Román M, López I, Guruceaga E, Baraibar I, Ecay M, Collantes M, Nadal E, Vallejo A, Cadenas S, Miguel ME, Jang JH, Martin-Uriz PS, Castro-Labrador L, Vilas-Zornoza A, Lara-Astiaso D, Ponz-Sarvise M, Rolfo C, Santos ES, Raez LE, Taverna S, Behrens C, Weder W, Wistuba II, Vicent S, Gil-Bazo I. Román M, et al. Among authors: nadal e. Cancer Res. 2019 Feb 1;79(3):625-638. doi: 10.1158/0008-5472.CAN-18-1479. Epub 2018 Dec 18. Cancer Res. 2019. PMID: 30563891
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy.
Zhang X, Tian D, Chen Y, Chen C, He LN, Zhou Y, Li H, Lin Z, Chen T, Wang Y, Russo A, Nadal E, Passiglia F, Soo RA, Watanabe S, Moran T, Oh IJ, Fu S, Hong S, Zhang L. Zhang X, et al. Among authors: nadal e. Transl Lung Cancer Res. 2021 Jul;10(7):3191-3202. doi: 10.21037/tlcr-21-455. Transl Lung Cancer Res. 2021. PMID: 34430357 Free PMC article.
Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications.
Hijazo-Pechero S, Alay A, Cordero D, Marín R, Vilariño N, Palmero R, Brenes J, Montalban-Casafont A, Nadal E, Solé X. Hijazo-Pechero S, et al. Among authors: nadal e. Mol Oncol. 2024 Feb;18(2):453-470. doi: 10.1002/1878-0261.13550. Epub 2023 Dec 21. Mol Oncol. 2024. PMID: 37943164 Free PMC article.
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
Nokin MJ, Darbo E, Travert C, Drogat B, Lacouture A, San José S, Cabrera N, Turcq B, Prouzet-Mauleon V, Falcone M, Villanueva A, Wang H, Herfs M, Mosteiro M, Jänne PA, Pujol JL, Maraver A, Barbacid M, Nadal E, Santamaría D, Ambrogio C. Nokin MJ, et al. Among authors: nadal e. JCI Insight. 2020 Aug 6;5(15):e137869. doi: 10.1172/jci.insight.137869. JCI Insight. 2020. PMID: 32759499 Free PMC article.
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.
Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, Leighl NB, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Blaquier JB, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Garrido P, Khan H, Baggi A, Mascaux C, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Métivier AC, Falchero L, Felip E, Genova C, Mazieres J, Tapan U, Brahmer J, Bria E, Puri S, Popat S, Reckamp KL, Morgillo F, Nadal E, Mazzoni F, Agustoni F, Bar J, Grosso F, Avrillon V, Patel JD, Gomes F, Ibrahim E, Trama A, Bettini AC, Barlesi F, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V; TERAVOLT study group. Whisenant JG, et al. Among authors: nadal e. J Thorac Oncol. 2022 May;17(5):661-674. doi: 10.1016/j.jtho.2021.12.015. Epub 2022 Feb 1. J Thorac Oncol. 2022. PMID: 35121086 Free PMC article.
Linkage of DNA methylation quantitative trait loci to human cancer risk.
Heyn H, Sayols S, Moutinho C, Vidal E, Sanchez-Mut JV, Stefansson OA, Nadal E, Moran S, Eyfjord JE, Gonzalez-Suarez E, Pujana MA, Esteller M. Heyn H, et al. Among authors: nadal e. Cell Rep. 2014 Apr 24;7(2):331-338. doi: 10.1016/j.celrep.2014.03.016. Epub 2014 Apr 3. Cell Rep. 2014. PMID: 24703846 Free article.
Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts.
Ambrogio C, Carmona FJ, Vidal A, Falcone M, Nieto P, Romero OA, Puertas S, Vizoso M, Nadal E, Poggio T, Sánchez-Céspedes M, Esteller M, Mulero F, Voena C, Chiarle R, Barbacid M, Santamaría D, Villanueva A. Ambrogio C, et al. Among authors: nadal e. Cancer Res. 2014 Nov 1;74(21):5978-88. doi: 10.1158/0008-5472.CAN-14-1606. Epub 2014 Sep 12. Cancer Res. 2014. PMID: 25217522
The role of Dickkopf-3 overexpression in esophageal adenocarcinoma.
Wang Z, Lin L, Thomas DG, Nadal E, Chang AC, Beer DG, Lin J. Wang Z, et al. Among authors: nadal e. J Thorac Cardiovasc Surg. 2015 Aug;150(2):377-385.e2. doi: 10.1016/j.jtcvs.2015.05.006. Epub 2015 May 8. J Thorac Cardiovasc Surg. 2015. PMID: 26093488 Free PMC article.
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.
Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, Blasco RB, Fernández-Marcos PJ, Sánchez-Céspedes M, Ren X, Wang Z, Ding K, Hidalgo M, Serrano M, Villanueva A, Santamaría D, Barbacid M. Ambrogio C, et al. Among authors: nadal e. Nat Med. 2016 Mar;22(3):270-7. doi: 10.1038/nm.4041. Epub 2016 Feb 8. Nat Med. 2016. PMID: 26855149
Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.
Evrard SM, Taranchon-Clermont E, Rouquette I, Murray S, Dintner S, Nam-Apostolopoulos YC, Bellosillo B, Varela-Rodriguez M, Nadal E, Wiedorn KH, Melchior L, Andrew E, Jones M, Ridgway J, Frykman C, Lind L, Rot M, Kern I, Speel EJM, Roemen GMJM, Trincheri N, Freiberger SN, Rechsteiner M. Evrard SM, et al. Among authors: nadal e. J Mol Diagn. 2019 Nov;21(6):1010-1024. doi: 10.1016/j.jmoldx.2019.06.010. Epub 2019 Aug 22. J Mol Diagn. 2019. PMID: 31445213 Free article.
Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer.
Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyàs E, Palmero R, Lopez-Bonet E, Hernández-Martínez A, Oliveras G, Buxó M, Izquierdo A, Morán T, Nadal E, Menendez JA. Bosch-Barrera J, et al. Among authors: nadal e. Cancers (Basel). 2021 Aug 19;13(16):4168. doi: 10.3390/cancers13164168. Cancers (Basel). 2021. PMID: 34439322 Free PMC article.
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
Aliagas E, Alay A, Martínez-Iniesta M, Hernández-Madrigal M, Cordero D, Gausachs M, Pros E, Saigí M, Busacca S, Sharkley AJ, Dawson A, Palmero R, Ruffinelli JC, Padrones S, Aso S, Escobar I, Ramos R, Llatjós R, Vidal A, Dorca E, Varela M, Sánchez-Céspedes M, Fennell D, Muñoz-Pinedo C, Villanueva A, Solé X, Nadal E. Aliagas E, et al. Among authors: nadal e. Br J Cancer. 2021 Nov;125(10):1365-1376. doi: 10.1038/s41416-021-01547-y. Epub 2021 Sep 29. Br J Cancer. 2021. PMID: 34588615 Free PMC article.
Two Patients With Advanced-Stage Lung Adenocarcinoma With Radiologic Complete Response to Nivolumab Treatment Harboring an STK11/LKB1 Mutation.
Nadal E, Heeke S, Benzaquen J, Vilariño N, Navarro A, Azuara D, Varela M, Otto J, Baixeras N, Shahbazian D, Puchois P, Church SE, Smith TH, Lanteri E, Ilié M, Hofman P. Nadal E, et al. JCO Precis Oncol. 2020 Nov;4:1239-1245. doi: 10.1200/PO.20.00174. JCO Precis Oncol. 2020. PMID: 35050781 No abstract available.
Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer.
Pio R, Garcia J, Corrales L, Ajona D, Fleischhacker M, Pajares MJ, Cardenal F, Seijo L, Zulueta JJ, Nadal E, Witt C, Lozano MD, Schmidt B, Montuenga LM. Pio R, et al. Among authors: nadal e. Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2665-72. doi: 10.1158/1055-9965.EPI-10-0467. Epub 2010 Aug 27. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20802023
Epigenetic regulation of vitamin D metabolism in human lung adenocarcinoma.
Ramnath N, Nadal E, Jeon CK, Sandoval J, Colacino J, Rozek LS, Christensen PJ, Esteller M, Beer DG, Kim SH. Ramnath N, et al. Among authors: nadal e. J Thorac Oncol. 2014 Apr;9(4):473-82. doi: 10.1097/JTO.0000000000000114. J Thorac Oncol. 2014. PMID: 24736069 Free PMC article.
Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.
Dhanasekaran SM, Balbin OA, Chen G, Nadal E, Kalyana-Sundaram S, Pan J, Veeneman B, Cao X, Malik R, Vats P, Wang R, Huang S, Zhong J, Jing X, Iyer M, Wu YM, Harms PW, Lin J, Reddy R, Brennan C, Palanisamy N, Chang AC, Truini A, Truini M, Robinson DR, Beer DG, Chinnaiyan AM. Dhanasekaran SM, et al. Among authors: nadal e. Nat Commun. 2014 Dec 22;5:5893. doi: 10.1038/ncomms6893. Nat Commun. 2014. PMID: 25531467 Free PMC article.
A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer.
Diaz-Lagares A, Mendez-Gonzalez J, Hervas D, Saigi M, Pajares MJ, Garcia D, Crujerias AB, Pio R, Montuenga LM, Zulueta J, Nadal E, Rosell A, Esteller M, Sandoval J. Diaz-Lagares A, et al. Among authors: nadal e. Clin Cancer Res. 2016 Jul 1;22(13):3361-71. doi: 10.1158/1078-0432.CCR-15-2346. Epub 2016 Feb 3. Clin Cancer Res. 2016. PMID: 26842235 Free article.
Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma.
Truini A, Coco S, Nadal E, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Biello F, Barletta G, Merlo DF, Valentino A, Ferro P, Ravetti GL, Stigliani S, Vigani A, Fedeli F, Beer DG, Roncella S, Grossi F. Truini A, et al. Among authors: nadal e. Oncotarget. 2017 Aug 2;8(40):68627-68640. doi: 10.18632/oncotarget.19800. eCollection 2017 Sep 15. Oncotarget. 2017. PMID: 28978143 Free PMC article.
MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer.
Saigi M, Alburquerque-Bejar JJ, Mc Leer-Florin A, Pereira C, Pros E, Romero OA, Baixeras N, Esteve-Codina A, Nadal E, Brambilla E, Sanchez-Cespedes M. Saigi M, et al. Among authors: nadal e. Clin Cancer Res. 2018 Sep 15;24(18):4579-4587. doi: 10.1158/1078-0432.CCR-18-0267. Epub 2018 Jun 13. Clin Cancer Res. 2018. PMID: 29898990
High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome.
Mezquita L, Jové M, Nadal E, Kfoury M, Morán T, Ricordel C, Dhooge M, Tlemsani C, Léna H, Teulé A, Álvarez JV, Raimbourg J, Hiret S, Lacroix L, Menéndez M, Saldaña J, Brunet J, Lianes P, Coupier I, Auclin E, Recondo G, Friboulet L, Adam J, Green E, Planchard D, Frébourg T, Capellà G, Rouleau E, Lázaro C, Caron O, Besse B. Mezquita L, et al. Among authors: nadal e. J Thorac Oncol. 2020 Jul;15(7):1232-1239. doi: 10.1016/j.jtho.2020.03.005. Epub 2020 Mar 14. J Thorac Oncol. 2020. PMID: 32179180 Free article.
Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cells.
Püschel F, Favaro F, Redondo-Pedraza J, Lucendo E, Iurlaro R, Marchetti S, Majem B, Eldering E, Nadal E, Ricci JE, Chevet E, Muñoz-Pinedo C. Püschel F, et al. Among authors: nadal e. Proc Natl Acad Sci U S A. 2020 May 5;117(18):9932-9941. doi: 10.1073/pnas.1913707117. Epub 2020 Apr 20. Proc Natl Acad Sci U S A. 2020. PMID: 32312819 Free PMC article.
Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project.
Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, de Perrot M, Brcic L, Nadal E, Tsimpoukis S, Gray SG, Ampollini L, Aerts JG, Felley-Bosco E, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, von der Thüsen J, Marti N, Vervita K, Kammler R, Peters S, Stahel RA, Baas P, Opitz I; ETOP Mesoscape consortium. Rüschoff JH, et al. Among authors: nadal e. Mod Pathol. 2022 Dec;35(12):1888-1899. doi: 10.1038/s41379-022-01145-0. Epub 2022 Sep 17. Mod Pathol. 2022. PMID: 36115922 Free PMC article.
Correction to: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project.
Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, de Perrot M, Brcic L, Nadal E, Tsimpoukis S, Gray SG, Ampollini L, Aerts JG, Felley-Bosco E, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, von der Thüsen J, Marti N, Vervita K, Kammler R, Peters S, Stahel RA, Baas P, Opitz I; ETOP Mesoscape consortium. Rüschoff JH, et al. Among authors: nadal e. Mod Pathol. 2022 Dec;35(12):2033. doi: 10.1038/s41379-022-01170-z. Mod Pathol. 2022. PMID: 36253399 Free PMC article. No abstract available.
A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma.
Nadal E, Zhong J, Lin J, Reddy RM, Ramnath N, Orringer MB, Chang AC, Beer DG, Chen G. Nadal E, et al. Clin Cancer Res. 2014 Jun 15;20(12):3107-17. doi: 10.1158/1078-0432.CCR-13-3348. Epub 2014 May 15. Clin Cancer Res. 2014. PMID: 24833665
Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer.
Delgado-García M, Weynand B, Gómez-Izquierdo L, Hernández MJ, Blanco ÁM, Varela M, Matias-Guiu X, Nadal E, Márquez-Lobo B, Alarcão A, de Álava E, Biscuola M. Delgado-García M, et al. Among authors: nadal e. BMC Cancer. 2020 Apr 3;20(1):275. doi: 10.1186/s12885-020-6697-7. BMC Cancer. 2020. PMID: 32245434 Free PMC article.
Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification.
Alay A, Cordero D, Hijazo-Pechero S, Aliagas E, Lopez-Doriga A, Marín R, Palmero R, Llatjós R, Escobar I, Ramos R, Padrones S, Moreno V, Nadal E, Solé X. Alay A, et al. Among authors: nadal e. J Immunother Cancer. 2021 Feb;9(2):e001601. doi: 10.1136/jitc-2020-001601. J Immunother Cancer. 2021. PMID: 33632900 Free PMC article.
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Banna GL, Addeo A, Zygoura P, Tsourti Z, Popat S, Curioni-Fontecedro A, Nadal E, Shah R, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Janthur WD, López-Castro R, Roschitzki-Voser H, Dafni U, Peters S, Stahel RA. Banna GL, et al. Among authors: nadal e. Lung Cancer. 2022 Jul;169:77-83. doi: 10.1016/j.lungcan.2022.05.018. Epub 2022 May 28. Lung Cancer. 2022. PMID: 35660972 Clinical Trial.
Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report.
Spira AI, Paz-Ares L, Han JY, Shih JY, Mascaux C, Roy UB, Zugazagoitia J, Kim YJ, Chiu CH, Kim SW, Nadal E, Gil-Bazo I, Murphy SP, Anderson BG, Xia Y, Wang G, Bauml JM, Chioda M, Simoes J, Mahadevia PJ, Lopes G. Spira AI, et al. Among authors: nadal e. J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00051-6. doi: 10.1016/j.jtho.2025.01.018. Online ahead of print. J Thorac Oncol. 2025. PMID: 39864547 Free article.
An eHealth ecosystem for stepped and early psychosocial care in advanced lung cancer: Rationale and protocol for a randomized control trial.
Ochoa-Arnedo C, Arizu-Onassis A, Medina JC, Flix-Valle A, Ciria-Suarez L, Gómez-Fernández D, Souto-Sampera A, Brao I, Palmero R, Nadal E, González-Barboteo J, Serra-Blasco M. Ochoa-Arnedo C, et al. Among authors: nadal e. Internet Interv. 2023 Apr 3;32:100620. doi: 10.1016/j.invent.2023.100620. eCollection 2023 Apr. Internet Interv. 2023. PMID: 37273934 Free PMC article.
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade.
Nokin MJ, Mira A, Patrucco E, Ricciuti B, Cousin S, Soubeyran I, San José S, Peirone S, Caizzi L, Vietti Michelina S, Bourdon A, Wang X, Alvarez-Villanueva D, Martínez-Iniesta M, Vidal A, Rodrigues T, García-Macías C, Awad MM, Nadal E, Villanueva A, Italiano A, Cereda M, Santamaría D, Ambrogio C. Nokin MJ, et al. Among authors: nadal e. Nat Commun. 2024 Aug 30;15(1):7554. doi: 10.1038/s41467-024-51828-2. Nat Commun. 2024. PMID: 39215000 Free PMC article.
Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.
Leary A, Estévez-García P, Sabatier R, Ray-Coquard I, Romeo M, Barretina-Ginesta P, Gil-Martin M, Garralda E, Bosch-Barrera J, Morán T, Martin-Martorell P, Nadal E, Gascón P, Rodon J, Lizcano JM, Muñoz-Guardiola P, Fierro-Durán G, Pedrós-Gámez O, Pérez-Montoyo H, Yeste-Velasco M, Cortal M, Pérez-Campos A, Alfon J, Domenech C, Pérez-Fidalgo A, Oaknin A. Leary A, et al. Among authors: nadal e. BMC Cancer. 2024 Jul 29;24(1):911. doi: 10.1186/s12885-024-12700-0. BMC Cancer. 2024. PMID: 39075404 Free PMC article. No abstract available.
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Nishino K, Yoh K, Shih JY, Chik JYK, Moro-Sibilot D, Puri T, Chacko Varughese S, Frimodt-Moller B, Visseren-Grul C, Reck M. Nakagawa K, et al. Among authors: nadal e. J Thorac Oncol. 2025 Apr;20(4):487-499. doi: 10.1016/j.jtho.2024.11.032. Epub 2024 Nov 30. J Thorac Oncol. 2025. PMID: 39622410 Free article. Clinical Trial.
Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project.
Haberecker M, Rüschoff JH, Andriakopoulou C, Gray SG, Nackaerts K, De Perrot M, Brcic L, Nadal E, Tsimpoukis S, Ampollini L, Aerts JG, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, Von Der Thüsen J, Vagenknecht P, Tsourti Z, Kerr KM, Kammler R, Peters S, Baas P, Opitz I, Stahel RA, Curioni-Fontecedro A; ETOP Mesoscape Consortium; TransSCOT Consortium. Haberecker M, et al. Among authors: nadal e. JCO Precis Oncol. 2025 Feb;9:e2400675. doi: 10.1200/PO-24-00675. Epub 2025 Feb 12. JCO Precis Oncol. 2025. PMID: 39938010
Pericardial Disease in Patients with Cancer: Clinical Insights on Diagnosis and Treatment.
Lorenzo-Esteller L, Ramos-Polo R, Pons Riverola A, Morillas H, Berdejo J, Pernas S, Pomares H, Asiain L, Garay A, Martínez Pérez E, Jiménez-Marrero S, Alcoberro L, Nadal E, Gubern-Prieto P, Gual-Capllonch F, Hidalgo E, Enjuanes C, Comin-Colet J, Moliner P. Lorenzo-Esteller L, et al. Among authors: nadal e. Cancers (Basel). 2024 Oct 12;16(20):3466. doi: 10.3390/cancers16203466. Cancers (Basel). 2024. PMID: 39456560 Free PMC article. Review.
New antiherpetic 1,3-phenylene derivatives, inhibitors of the interaction of the HSV-1 origin binding protein (OBP) with DNA.
Font M, Sanmartín C, Alonso ML, Gracia L, Losa MJ, Marquiegui B, Merino I, Nadal E, Ruiz I, Monge A, Bengoechea MT, Cabodevilla F, Elena S, Martinez-Irujo JJ, Odriozola L, Peñuelas I, Santiago E, Homa F, Wathen MW. Font M, et al. Among authors: nadal e. Drug Des Discov. 2000;16(4):295-315. Drug Des Discov. 2000. PMID: 10807035
Reply to E.J. Lehrer et al and J.B. De Vis et al.
Nadal E, Vilariño N, Simó M, Navarro V, Bruna J. Nadal E, et al. J Clin Oncol. 2024 Mar 1;42(7):859-861. doi: 10.1200/JCO.23.02248. Epub 2023 Dec 11. J Clin Oncol. 2024. PMID: 38079584 No abstract available.
Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study.
Varela M, Teixidó C, Álvarez-Fernández C, Arasanz H, Peralta S, Lázaro M, Calvo V, Álvarez R, Baena J, Valdivia J, Arriola E, Bernabé R, Isla D, Camacho C, Massutí B, Blasco A, García T, Cobo M, Campayo M, Hijazo-Pechero S, Callejo Á, Domínguez M, Nadal E. Varela M, et al. Among authors: nadal e. Transl Lung Cancer Res. 2025 Apr 30;14(4):1254-1265. doi: 10.21037/tlcr-2024-1146. Epub 2025 Apr 21. Transl Lung Cancer Res. 2025. PMID: 40386732 Free PMC article.
Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain.
Calles A, Alonso M, Martín-Martorell P, Gómez A, de Castro J, Martínez-Aguillo M, Estival A, Mosquera J, Martínez-Banaclocha N, Majem M, Reyes R, Azkona E, Ortega AL, Aguin S, Santos A, Aguilar A, Cucurull M, Blasco A, Calvo V, Isla D, Nadal E, Aguado C, Sais E, Juan-Vidal O, Diz-Taín M, Taus Á, Villanueva N, Bayona C, Amenedo M, Mielgo X, Arriola E, Baena J; Spanish Lung Cancer Group. Calles A, et al. Among authors: nadal e. Cancer Treat Res Commun. 2025 Mar 22;43:100905. doi: 10.1016/j.ctarc.2025.100905. Online ahead of print. Cancer Treat Res Commun. 2025. PMID: 40154161 Free article.
Transcriptional heterogeneity shapes stress-adaptive responses in yeast.
Nadal-Ribelles M, Lieb G, Solé C, Matas Y, Szachnowski U, Andjus S, Quintana M, Romo M, Herrero AG, Morillon A, Pelet S, de Nadal E, Posas F. Nadal-Ribelles M, et al. Among authors: de nadal e. Nat Commun. 2025 Mar 17;16(1):2631. doi: 10.1038/s41467-025-57911-6. Nat Commun. 2025. PMID: 40097446 Free PMC article.
Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis.
Isla D, Álvarez R, Arnal M, Arriola E, Azkarate A, Azkona E, García-Campelo R, Garrido P, Nadal E, Ortega AL, Carcedo D, Crespo M, Lavara J, Córcoles F, Bernabé R. Isla D, et al. Among authors: nadal e. J Med Econ. 2024 Jan-Dec;27(1):1379-1387. doi: 10.1080/13696998.2024.2413289. Epub 2024 Oct 23. J Med Econ. 2024. PMID: 39387325 Free article.
Urinary soluble PD-1 as a biomarker of checkpoint inhibitor-induced acute tubulointerstitial nephritis.
Gomez-Preciado F, Martinez-Valenzuela L, Anton-Pampols P, Fulladosa X, Tena MG, Gomà M, Jove M, Nadal E, Merino-Ribas A, Martin-Alemany N, Cruzado JM, Torras J, Draibe J. Gomez-Preciado F, et al. Among authors: nadal e. Clin Kidney J. 2024 Jul 2;17(8):sfae200. doi: 10.1093/ckj/sfae200. eCollection 2024 Aug. Clin Kidney J. 2024. PMID: 39131079 Free PMC article.
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma.
Nokin MJ, Darbo E, Richard E, San José S, de Hita S, Prouzet-Mauleon V, Turcq B, Gerardelli L, Crake R, Velasco V, Koopmansch B, Lambert F, Xue JY, Sang B, Horne J, Ziemons E, Villanueva A, Blomme A, Herfs M, Cataldo D, Calvayrac O, Porporato P, Nadal E, Lito P, Jänne PA, Ricciuti B, Awad MM, Ambrogio C, Santamaría D; Bolero Consortium. Nokin MJ, et al. Among authors: nadal e. Cell Rep Med. 2024 Aug 20;5(8):101663. doi: 10.1016/j.xcrm.2024.101663. Epub 2024 Aug 1. Cell Rep Med. 2024. PMID: 39094577 Free PMC article.
Bridging the divide: addressing discrepancies between clinical guidelines, policy guidelines, and biomarker utilization.
Horgan D, Hofman P, Buttner R, Rieß O, Lugowska I, Dube F, Singh J, Nadal E, Stokłosa T, Sīviņa E, Van der Buckle M, Mosoiu S, Bertolaccini L, Girard N, Meerbeeck JV, Omar I, Capoluongo ED, Bielack S, Hills T, Baldwin D, Subbiah V. Horgan D, et al. Among authors: nadal e. Diagnosis (Berl). 2024 Aug 1;12(1):94-107. doi: 10.1515/dx-2024-0092. eCollection 2025 Feb 1. Diagnosis (Berl). 2024. PMID: 39088796
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC.
Reck M, Nadal E, Girard N, Filippi AR, Martin LW, Gay CM, Petersen C, Gale D, Emeribe UA, Georgoulia N, Perez IED, Spicer JD. Reck M, et al. Among authors: nadal e. Clin Lung Cancer. 2024 Sep;25(6):587-593.e3. doi: 10.1016/j.cllc.2024.06.007. Epub 2024 Jun 21. Clin Lung Cancer. 2024. PMID: 39003185 Free article.
The rise of single-cell transcriptomics in yeast.
Nadal-Ribelles M, Solé C, de Nadal E, Posas F. Nadal-Ribelles M, et al. Yeast. 2024 Apr;41(4):158-170. doi: 10.1002/yea.3934. Epub 2024 Feb 25. Yeast. 2024. PMID: 38403881 Free article. Review.
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer.
Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussein M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE. Riely GJ, et al. Among authors: nadal e. Future Oncol. 2024;20(16):1047-1055. doi: 10.2217/fon-2023-0859. Epub 2024 Feb 15. Future Oncol. 2024. PMID: 38357801 Free PMC article.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. Zhou C, et al. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Free PMC article. Clinical Trial.
Difficulties on the access to innovative targeted therapies for lung cancer in Spain.
Calvo V, Camps C, Carcereny E, Cobo M, Dómine M, García Campelo MR, González Larriba JL, Guirado M, Hernando-Trancho F, Massutí B, Nadal E, Rodríguez-Abreu D, Sánchez A, Sullivan IG, Provencio M; Spanish Lung Cancer Group (SLCG/GECP). Calvo V, et al. Among authors: nadal e. Clin Transl Oncol. 2024 Mar;26(3):597-612. doi: 10.1007/s12094-023-03303-5. Epub 2023 Aug 31. Clin Transl Oncol. 2024. PMID: 37651020 Free PMC article. Review.
European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
Opitz I, Bille A, Dafni U, Nackaerts K, Ampollini L, de Perrot M, Brcic L, Nadal E, Syrigos K, Gray SG, Aerts J, Curioni-Fontecedro A, Rüschoff JH, Monkhorst K, Weynand B, Silini EM, Bavaghar-Zaeimi F, Jakopovic M, Llatjos R, Tsimpoukis S, Finn SP, von der Thüsen J, Marti N, Dimopoulou G, Kammler R, Peters S, Stahel RA, Falcoz PE, Brunelli A, Baas P; ETOP Mesoscape and ESTS Consortia. Opitz I, et al. Among authors: nadal e. J Thorac Oncol. 2023 Sep;18(9):1233-1247. doi: 10.1016/j.jtho.2023.06.011. Epub 2023 Jun 23. J Thorac Oncol. 2023. PMID: 37356802 Free article.
A Genome-Wide Functional Screen Identifies Enhancer and Protective Genes for Amyloid Beta-Peptide Toxicity.
Picón-Pagès P, Bosch-Morató M, Subirana L, Rubio-Moscardó F, Guivernau B, Fanlo-Ucar H, Zeylan ME, Senyuz S, Herrera-Fernández V, Vicente R, Fernández-Fernández JM, García-Ojalvo J, Gursoy A, Keskin O, Oliva B, Posas F, de Nadal E, Muñoz FJ. Picón-Pagès P, et al. Int J Mol Sci. 2023 Jan 9;24(2):1278. doi: 10.3390/ijms24021278. Int J Mol Sci. 2023. PMID: 36674792 Free PMC article.
3D collagen migration patterns reveal a SMAD3-dependent and TGF-β1-independent mechanism of recruitment for tumour-associated fibroblasts in lung adenocarcinoma.
Juste-Lanas Y, Díaz-Valdivia N, Llorente A, Ikemori R, Bernardo A, Arshakyan M, Borau C, Ramírez J, Ruffinelli JC, Nadal E, Reguart N, García-Aznar JM, Alcaraz J. Juste-Lanas Y, et al. Among authors: nadal e. Br J Cancer. 2023 Apr;128(6):967-981. doi: 10.1038/s41416-022-02093-x. Epub 2022 Dec 26. Br J Cancer. 2023. PMID: 36572730 Free PMC article.
Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program.
Jiménez C, Antonelli R, Nadal-Ribelles M, Devis-Jauregui L, Latorre P, Solé C, Masanas M, Molero-Valenzuela A, Soriano A, Sánchez de Toledo J, Llobet-Navas D, Roma J, Posas F, de Nadal E, Gallego S, Moreno L, Segura MF. Jiménez C, et al. Among authors: nadal ribelles m. Mol Cancer. 2022 Sep 3;21(1):175. doi: 10.1186/s12943-022-01643-4. Mol Cancer. 2022. PMID: 36057593 Free PMC article.
Data-driven identification of inherent features of eukaryotic stress-responsive genes.
Latorre P, Böttcher R, Nadal-Ribelles M, Li CH, Solé C, Martínez-Cebrián G, Boutros PC, Posas F, de Nadal E. Latorre P, et al. Among authors: nadal ribelles m. NAR Genom Bioinform. 2022 Mar 7;4(1):lqac018. doi: 10.1093/nargab/lqac018. eCollection 2022 Mar. NAR Genom Bioinform. 2022. PMID: 35265837 Free PMC article.
Hog1 activation delays mitotic exit via phosphorylation of Net1.
Tognetti S, Jiménez J, Viganò M, Duch A, Queralt E, de Nadal E, Posas F. Tognetti S, et al. Proc Natl Acad Sci U S A. 2020 Apr 21;117(16):8924-8933. doi: 10.1073/pnas.1918308117. Epub 2020 Apr 7. Proc Natl Acad Sci U S A. 2020. PMID: 32265285 Free PMC article.
The p38 Pathway: From Biology to Cancer Therapy.
Martínez-Limón A, Joaquin M, Caballero M, Posas F, de Nadal E. Martínez-Limón A, et al. Int J Mol Sci. 2020 Mar 11;21(6):1913. doi: 10.3390/ijms21061913. Int J Mol Sci. 2020. PMID: 32168915 Free PMC article. Review.
307 results